Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
ConclusionsThis real-world US cohort analysis described patients with PsA newly initiating tofacitinib; most were bDMARD-experienced or receiving monotherapy treatment. In patients who remained on therapy (48.8%), tofacitinib was effective across multiple PsA domains at 6 ± 3 months. Limitations included small patient numbers at follow-up and potential selection bias.Trial RegistrationClinicalTrials.gov identifier, NCT05195814.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Arthritis | Disability | Methotrexate | Pain | Psoriatic Arthritis | Rheumatology | Skin | Study